GLSI · Greenwich LifeSciences, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued.”View the 10-Q filed Jun 4, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-29 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
700 |
| 2026-07-28 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
1,500 |
| 2026-07-27 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
1,500 |
| 2026-07-24 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
1,100 |
| 2026-07-23 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
2,500 |
| 2026-01-13 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
1,800 |
| 2026-01-12 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
2,900 |
| 2025-12-31 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
4,300 |
| 2025-12-30 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
2,900 |
| 2025-12-18 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
4,100 |
| 2025-11-25 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
4,600 |
| 2025-11-13 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Award↑
|
Stock Options
|
100,000 |
| 2025-11-07 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
10,600 |
| 2025-10-31 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
2,300 |
| 2025-04-25 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
3,600 |
| 2025-04-17 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
5,400 |
| 2025-04-07 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
3,600 |
| 2025-04-04 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
5,500 |
| 2025-01-10 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
2,500 |
| 2025-01-07 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
1,800 |
| 2025-01-06 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
1,100 |
| 2025-01-03 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
3,400 |
| 2025-01-02 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
2,000 |
| 2024-12-31 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
2,400 |
| 2024-12-30 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
3,200 |
| 2024-12-24 | Hallock Kenneth |
Director |
Award↑
Filing footnotes — Stock Options (Direct)
10,337 options vest and are exercisable upon date of grant and the remainder vest and are exercisable monthly over 36 months. |
Stock Options
|
41,349 |
| 2024-12-24 | Thompson Jaye |
VP Clinical Reg Affairs |
Award↑
Filing footnotes — Stock Options (Direct)
37,455 options are earned upon date of grant and the remainder are earned monthly over 36 months. 10% of the earned options vest if reporting person has been employed by Issuer between 1-2 years from grant date, 20% of the earned options vest if reporting person has been employed by Issuer between 2-3 years from grant date, 30% of the earned options vest if reporting person has been employed by Issuer between 3-4 years from grant date and the remaining earned options vest if reporting person has been employed by Issuer more than 4 years after grant date. |
Stock Options
|
149,818 |
| 2024-12-24 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Award↑
Filing footnotes — Stock Options (Direct)
262,181 options are earned upon date of grant and 786,542 options are earned monthly over 36 months. 10% of the earned options vest if reporting person has been employed by Issuer between 1-2 years from grant date, 20% of the earned options vest if reporting person has been employed by Issuer between 2-3 years from grant date, 30% of the earned options vest if reporting person has been employed by Issuer between 3-4 years from grant date and the remaining earned options vest if reporting person has been employed by Issuer more than 4 years after grant date. 100,000 options are earned and vest upon date of grant. |
Stock Options
|
1,148,723 |
| 2024-12-24 | Daugherty Frank Joseph |
Director, Chief Medical Officer |
Award↑
Filing footnotes — Stock Options (Direct)
26,233 options are earned upon date of grant and the remainder are earned monthly over 36 months. 10% of the earned options vest if reporting person has been employed by Issuer between 1-2 years from grant date, 20% of the earned options vest if reporting person has been employed by Issuer between 2-3 years from grant date, 30% of the earned options vest if reporting person has been employed by Issuer between 3-4 years from grant date and the remaining earned options vest if reporting person has been employed by Issuer more than 4 years after grant date. |
Stock Options
|
104,890 |
| 2024-12-24 | Rothe Eric |
Director |
Award↑
Filing footnotes — Stock Options (Direct)
10,337 options vest and are exercisable upon date of grant and the remainder vest and are exercisable monthly over 36 months. |
Stock Options
|
41,349 |
| 2024-12-24 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Award↑
Filing footnotes — Stock Options (Indirect)
6,252 options are earned and vest upon date of grant and the remainder are earned and vest monthly over 36 months. |
Stock Options
(I)
|
25,008 |
| 2024-12-24 | McWilliams David |
Director |
Award↑
Filing footnotes — Stock Options (Direct)
15,496 options vest and are exercisable upon date of grant and the remainder vest and are exercisable monthly over 36 months. |
Stock Options
|
61,984 |
| 2024-11-21 | Thompson Jaye |
VP Clinical Reg Affairs |
Buy↑
|
Common Stock
|
1,000 |
| 2024-09-26 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
1,500 |
| 2024-08-12 | Thompson Jaye |
VP Clinical Reg Affairs |
Buy↑
|
Common Stock
|
800 |
| 2024-08-06 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
2,000 |
| 2024-08-05 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
5,500 |
| 2024-08-02 | Thompson Jaye |
VP Clinical Reg Affairs |
Buy↑
|
Common Stock
|
1,000 |
| 2024-07-23 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
1,500 |
| 2024-07-18 | Thompson Jaye |
VP Clinical Reg Affairs |
Buy↑
|
Common Stock
|
1,000 |
| 2024-06-13 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
174,825 |
| 2024-04-01 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
3,000 |
| 2024-03-22 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
2,500 |
| 2024-03-20 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
1,500 |
| 2024-03-05 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
3,500 |
| 2024-03-04 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
4,100 |
| 2024-02-16 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
10,800 |
| 2024-02-15 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
12,700 |
| 2023-11-10 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
5,000 |
| 2023-11-03 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
3,500 |